DALLAS, April 17 ACCESS PHARMACEUTICALS, INC.(OTC Bulletin Board: ACCP) announced results from preclinical studies ongoingat the prestigious Imperial College London on Angiolix(R), a proprietaryhumanized monoclonal antibody. The new data, presented by Dr. MahendraDeonarain and Laura Bonney, Department of Biochemistry, demonstrate thatAngiolix has unusually high accumulation in multiple solid tumor types,including breast and ovarian cancer. Angiolix interferes with binding of aproprietary marker known as lactadherin, which is produced by cancer cells andbinds to an adhesion molecule specifically expressed on new blood vesselsproduced by tumors. Lactadherin is not expressed in normal tissues andtherefore it is a suitable marker for tumor targeting. Angiolix has previouslybeen shown by the Cancer Institute of Contra Costa in San Francisco to be ableto destroy transplanted human breast cancer tumors.
"This new data shows that Angiolix interferes with binding of lactadherinon new blood vessels and many different tumor types including breast, ovary,stomach, as well with surrounding tissues the extra cellular matrix aroundtumors and new blood vessels formed by tumors. Angiolix has similar effects toAvastin(R) (Genentech). Avastin targets VEGF instead of lactadherin and sinceAngiolix works on a different pathway to Avastin, it could potentially besynergistic," said Agamemnon Epenetos, Ph.D., Access' Chief ScientificOfficer - Europe. "We believe this two-pronged attack could potentiallyinhibit the process of angiogenesis and also induce apoptosis, promotingcancer cell death. Based on this data, we are commencing additional studieswhere Angiolix is administered in combination with chemotherapy in multipletumor types, including breast and ovarian cancers."
"No other product against the unique tumor marker, Lactadherin, for thetreatment of cancer can be developed without a sub-license from AccessPharmaceuticals," continued Dr. Epenetos.
Angiolix is a humanized monoclonal antibody that binds to a proprietarytarget called Lactadherin. Lactadherin has a critical role in promoting thegrowth of new blood vessels to support tumor growth through activation ofVEGF-mediated angiogenesis. Angiolix demonstrated high tumor accumulation bybinding to available lactadherin on the tumor and surrounding tissue. In priorhuman breast tumor mouse models, mice treated with Angiolix showed asignificant reduction in tumor volume while tumors in untreated controls grew10-fold over the 30-day treatment period. Access is actively seekingco-development partners for Angiolix.
Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company thatdevelops and commercializes propriety products for the treatment andsupportive care of cancer patients. Access' products include ProLindac(TM),currently in Phase 2 clinical testing of patients with ovarian cancer, andMuGard(TM) for the management of patients with mucositis. The Company also hasother advanced drug delivery technologies including Cobalamin(TM)-mediatedtargeted delivery and oral drug delivery, its proprietary nanopolymer deliverytechnology based on the natural vitamin B12 uptake mechanism; Angiolix(R), ahumanized monoclonal antibody which acts as an anti-angiogenesis factor and istargeted to breast cancer; Prodrax(R), a non-toxic prodrug which is activatedin the hypoxic zones of solid tumors to kill cancer cells; Alchemix, achemotherapeutic agent that combines multiple modes of action to overcome drugresistance. Access is also developing Phenylbutyrate ("PB"), an HDAC inhibitorand differentiating agent currently a Phase 2 clinical candidate. Foradditional information on Access Pharmaceuticals, please visit our website athttp://www.accesspharma.com.
This press release contains certain statements that are forward-lookingwithin the meaning of Section 27a of th